We at BioWorld actually contemplated putting out a zany blog about biotech to commemorate April Fools’ Day – i.e. biotech firm develops drug for childhood cooties, or something equally ridiculous – but, in the end, we decided to pass. And…
Author Archives: Jennifer Boggs
Big Wins, a Cliff, a Race and a Red Face: A 2012 Recap
December 21, 2012 – 9:08 am
Now that 2012 is drawing to a close, it’s once again time to take a look back at a year that saw some big hits and misses for the biotech industry – and there were plenty of both. The hits…
#BIO2012: Tips for a Wicked Good Meeting
June 14, 2012 – 3:57 pm
Heading to Boston next week for the 2012 Biotechnology Industry Organization International convention? So are we. In fact, BioWorld has attended and exhibited at the annual BIO meeting for 18 years, so we know a thing or two about navigating…
Profit vs. Value: When Activist Shareholders Attack
April 11, 2012 – 3:09 pm
Amylin Pharmaceuticals Inc.’s board dodged a dissident shareholder bullet three years ago, but the San Diego-based biotech is back in the crosshairs of billionaire investor and activist shareholder Carl Icahn, who again is seeking to nominate a new slate of…
Reason Free from Passion? That’s Not Biotech
October 27, 2011 – 9:24 am
SAN FRANCISCO ‑ At this week’s BIO Investor Forum in San Francisco, there was talk of how the biotech industry has squandered money, paying for infrastructure when it should have been paying only for development and continuing to fund programs…
What’s in a Biotech Name? It’s Greek to Me
October 13, 2011 – 2:13 pm
OK, you’re a biotech entrepreneur and you’ve found some interesting new technology. You’ve secured some seed funding, found some lab space and filled out all the appropriate paperwork for a business license. All’s that left to incorporate your brand new…
Will Dendreon’s Slide Force Cancer Vaccines Out of Style?
September 13, 2011 – 9:20 am
Back in 2008, biotech companies working on cancer vaccines were not exactly shouting it from the rooftops. In fact, most companies working in the space quietly began branding their drug candidates “immunotherapies” when they met with investors in an attempt…
Join the Conversation